Short-term discontinuation of HAART regimens more common in vulnerable patient populations

AIDS Research and Human Retroviruses

Volumn 24, Issue 11, 2008, Pages 1347-1355

  Robison, Lindsay S ^a   Westfall, Andrew O ^a   Mugavero, Michael J ^a,c   Kempf, Mirjam C ^a   Cole, Stephen R ^b   Allison, Jeroan J ^a   Willig, James H ^a   Raper, James L ^a   Wilcox, C Mel ^a   Saag, Michael S ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c CCB 142 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AFRICAN AMERICAN; ARTICLE; COHORT ANALYSIS; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; PRIVATE HEALTH INSURANCE; RETROSPECTIVE STUDY; SOCIAL PSYCHOLOGY;

ADULT; AGE FACTORS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; SOCIOECONOMIC FACTORS; SUBSTANCE ABUSE, INTRAVENOUS; UNITED STATES;

EID: 57049157204     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2008.0083     Document Type: Article

References (36)

1. O'Brien ME, Clark RA, Besch CL, Myers L, and Kissinger P: Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. J Acquir Immune Defic Syndr 2003;34:407-414.
2. Hogg RS, Heath KV, Yip B, et al.: Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998;279:450-454.
3. Powderly WG, Landay A, and Lederman MM: Recovery of the immune system with antiretroviral therapy: The end of opportunism? JAMA 1998;280:72-77.
4. Palella FJ Jr, Delaney KM, Moorman AC, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-860.
5. Ledergerber B, Egger M, Opravil M, et al.: Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study. Swiss HIV Cohort Study. Lancet 1999;353:863-868.
6. Haubrich RH, Little SJ, Currier JS, et al.: The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group. AIDS 1999;13:1099-1107.
7. d'Arminio Monforte A, Lepri AC, Rezza G, et al.: Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naive Patients. AIDS 2000;14:499-507.
8. Vanhove GF, Schapiro JM, Winters MA, Merigan TC, and Blaschke TF: Patient compliance and drug failure in protease inhibitor monotherapy. JAMA 1996;276:1955-1956.
9. Bassetti S, Battegay M, Furrer H, et al.: Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 1999;21:114-119.
10. Bonfanti P, Valsecchi L, Parazzini F, et al.: Incidence of adverse reactions in HIV patients treated with protease inhibitors: A cohort study. Coordinamento Italiano Studio Allergia e Infezione da HIV (CISAI) Group. J Acquir Immune Defic Syndr 2000;23:236-245.
11. Dorrucci M, Pezzotti P, Grisorio B, et al.: Time to discontinuation of the first highly active antiretroviral therapy regimen: A comparison between protease inhibitor- and non-nucleoside reverse transcriptase inhibitor-containing regimens. AIDS 2001;15:1733-1736.
12. Hansel A, Bucher HC, Nuesch R, and Battegay M: Reasons for discontinuation of first highly active antiretroviral therapy in a cohort of proteinase inhibitor-naive HIV-infected patients. J Acquir Immune Defic Syndr 2001;26:191-193.
13. Le Moing V, Chene G, Leport C, et al.: Impact of discontinuation of initial protease inhibitor therapy on further virological response in a cohort of human immunodeficiency virus-infected patients. Clin Infect Dis 2002;34:239-247.
14. Cozzi-Lepri A, Phillips AN, d'Arminio Monforte A, et al.: Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naive Antiretrovirals (I.Co.N.A.) study. J Infect Dis 2002;185:1062-1069.
15. Chen RY, Westfall AO, Mugavero MJ, et al.: Duration of highly active antiretroviral therapy regimens. Clin Infect Dis 2003;37:714-722.
16. Staszewski S, Morales-Ramirez J, Tashima KT, et al.: Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 1999;341:1865-1873.
17. Chen RY, Accortt NA, Westfall AO, et al.: Distribution of health care expenditures for HIV-infected patients. Clin Infect Dis 2006;42:1003-1010.
18. Willig JH, Westfall AO, Allison J, et al.: Nucleoside reverse-transcriptase inhibitor dosing errors in an outpatient HIV clinic in the electronic medical record era. Clin Infect Dis 2007;45:658-661.
19. Lucas GM, Chaisson RE, and Moore RD: Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999;131:81-87.
20. Visnegarwala F, Graviss EA, Sajja P, Lahart CJ, and White AC Jr.: Determinants of sustained virological suppression in indigent, HIV-infected patients: Is single protease inhibitor-based antiretroviral therapy truly highly active? HIV Clin Trials 2004;5:117-124.
21. Visnegarwala F, Rodriguez-Barradass MC, Graviss EA, Caprio M, Nykyforchyn M, and Laufman L: Community outreach with weekly delivery of anti-retroviral drugs compared to cognitive-behavioural health care team-based approach to improve adherence among indigent women newly starting HAART. AIDS Care 2006;18:332-338.
22. Yuan Y, L'Italien G, Mukherjee J, and Iloeje UH: Determinants of discontinuation of initial highly active antiretroviral therapy regimens in a US HIV-infected patient cohort. HIV Med 2006;7:156-162.
23. Ofotokun I and Pomeroy C: Sex differences in adverse reactions to antiretroviral drugs. Top HIV Med 2003;11:55-59.
24. Update: trends in AIDS incidence - United States, 1996. MMWR Morb Mortal Wkly Rep 1997;46:861-867.
25. Hader SL, Smith DK, Moore JS, and Holmberg SD: HIV infection in women in the United States: Status at the Millennium. JAMA 2001;285:1186-1192.
26. Demas PSE, Hirky AE, Wills TA, Doll LS, Hartel DM, and Klein RS: The relationship of HIV treatment acceptance and adherence to psychological factors among injection drug users. AIDS Behavior 1998;2:283-292.
27. Kerr T, Marshall A, Walsh J, et al.: Determinants of HAART discontinuation among injection drug users. AIDS Care 2005;17:539-549.
28. Palepu A, Tyndall M, Li K, Yip B, Hogg RS, O'shaughnessy MV, Montaner JSG, and Schecter M: Access and sustainability of antiretroviral therapy among injection drug users in Vancouver. Can J Infect Dis 2005;Suppl B:32B.
29. Lucas GM, Griswold M, Gebo KA, Keruly J, Chaisson RE, and Moore RD: Illicit drug use and HIV-1 disease progression: A longitudinal study in the era of highly active antiretroviral therapy. Am J Epidemiol 2006;163:412-420.
30. Gulick RM, Ribaudo HJ, Shikuma CM, et al.: Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: A randomized controlled trial. JAMA 2006;296:769-781.
31. Pence BW, Ostermann J, Kumar V, Whetten K, Thielman N, and Mugavero MJ: The influence of psychosocial characteristics and race/ethnicity on the use, duration, and success of antiretroviral therapy. J Acquir Immune Defic Syndr 2008;47:194-201.
32. Mugavero MJ, Lin HY, Allison JJ, et al.: Failure to establish HIV care: Characterizing the "no show" phenomenon. Clin Infect Dis 2007;45:127-130.
33. Catz SL, McClure JB, Jones GN, and Brantley PJ: Predictors of outpatient medical appointment attendance among persons with HIV. AIDS Care 1999;11:361-373.
34. Israelski D, Gore-Felton C, Power R, Wood MJ, and Koopman C: Sociodemographic characteristics associated with medical appointment adherence among HIV-seropositive patients seeking treatment in a county outpatient facility. Prev Med 2001;33:470-475.
35. Ammassari A, Murri R, Pezzotti P, et al.: Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr 2001;28:445-449.
36. Justice AC, Rabeneck L, Hays RD, Wu AW, and Bozzette SA: Sensitivity, specificity, reliability, and clinical validity of provider-reported symptoms: A comparison with self-reported symptoms. Outcomes Committee of the AIDS Clinical Trials Group. J Acquir Immune Defic Syndr 1999;21:126-133.